{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplastic+Disease+%28Disorder%29&page=8", "query": { "condition": "Malignant Neoplastic Disease (Disorder)", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 2474, "total_pages": 248, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplastic+Disease+%28Disorder%29&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplastic+Disease+%28Disorder%29&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T20:16:29.907Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00671970", "title": "Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Bevacizumab and Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2007-02", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2013-05-13", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671970" }, { "nct_id": "NCT02333188", "title": "Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of Unknown Primary", "Adult Cholangiocarcinoma", "Gallbladder Carcinoma", "Gastric Adenocarcinoma", "Malignant Gastrointestinal Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma", "Stage III Ampulla of Vater Cancer", "Stage III Pancreatic Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gallbladder Cancer", "Stage IIIB Gastric Cancer", "Stage IV Ampulla of Vater Cancer", "Stage IV Gallbladder Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-12", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 8, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02333188" }, { "nct_id": "NCT00108069", "title": "Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "Tamoxifen citrate", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2005-04", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2015-11-05", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108069" }, { "nct_id": "NCT04370834", "title": "Tocilizumab for Patients With Cancer and COVID-19 Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Pneumonia", "Pneumonitis", "Severe Acute Respiratory Distress Syndrome", "Symptomatic COVID-19 Infection Laboratory-Confirmed" ], "interventions": [ { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 1, "start_date": "2020-05-28", "completion_date": "2021-01-14", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 5, "location_summary": "Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Rockville", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04370834" }, { "nct_id": "NCT03173950", "title": "Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma", "Ependymoma", "Pineal Region Tumors", "Choroid Plexus Tumors", "Atypical/Malignant Meningioma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain and/or spine", "type": "DIAGNOSTIC_TEST" }, { "name": "Body CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "MDASI-BT", "type": "OTHER" }, { "name": "MDASI-SP", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 136, "start_date": "2017-07-13", "completion_date": "2025-06-23", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 3, "location_summary": "Chicago, Illinois • Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03173950" }, { "nct_id": "NCT06305884", "title": "Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic and Lymphoid System Neoplasm", "Lymphedema", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Bioelectric Impedance Analysis", "type": "PROCEDURE" }, { "name": "Exercise", "type": "OTHER" }, { "name": "Photoplethysmography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "BEHAVIORAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BEHAVIORAL" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 76, "start_date": "2024-04-22", "completion_date": "2025-12-17", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06305884" }, { "nct_id": "NCT02632071", "title": "ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Breast Carcinoma" ], "interventions": [ { "name": "ACY-1215", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2016-03-01", "completion_date": "2020-09-30", "has_results": false, "last_update_posted_date": "2021-01-07", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632071" }, { "nct_id": "NCT03175432", "title": "Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRAF V600 Wild Type", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Intracranial Melanoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Refractory Melanoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-06-15", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175432" }, { "nct_id": "NCT00024258", "title": "Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 22, "start_date": "2001-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2015-11-25", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024258" }, { "nct_id": "NCT02159898", "title": "EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Esophageal Strictures" ], "interventions": [ { "name": "EndoMAXX Endoluminal Valve Technology (EVT)", "type": "DEVICE" }, { "name": "EndoMAXX", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Merit Medical Systems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2015-01", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-06-07", "last_synced_at": "2026-10-14T20:16:29.907Z", "location_count": 7, "location_summary": "Aurora, Colorado • Gainesville, Florida • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02159898" } ] }